Literature DB >> 30430027

Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?

Wei Guo1, Su Yang1, Wentian Zhang1, Hecheng Li1, Bo Lu2.   

Abstract

Entities:  

Year:  2018        PMID： 30430027      PMCID： PMC6186643          DOI： 10.21037/jtd.2018.07.84

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  Lung cancer--time to move on from chemotherapy.

Authors:  Desmond N Carney
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

2.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors:  Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal:  Lancet Oncol       Date:  2016-10-10       Impact factor: 41.316

3.  Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Authors:  Scott Gettinger; Leora Horn; David Jackman; David Spigel; Scott Antonia; Matthew Hellmann; John Powderly; Rebecca Heist; Lecia V Sequist; David C Smith; Philip Leming; William J Geese; Dennis Yoon; Ang Li; Julie Brahmer
Journal:  J Clin Oncol       Date:  2018-03-23       Impact factor: 44.544

Review 4.  Scientific Advances in Lung Cancer 2015.

Authors:  Anne S Tsao; Giorgio V Scagliotti; Paul A Bunn; David P Carbone; Graham W Warren; Chunxue Bai; Harry J de Koning; A Uraujh Yousaf-Khan; Annette McWilliams; Ming Sound Tsao; Prasad S Adusumilli; Ramón Rami-Porta; Hisao Asamura; Paul E Van Schil; Gail E Darling; Suresh S Ramalingam; Daniel R Gomez; Kenneth E Rosenzweig; Stefan Zimmermann; Solange Peters; Sai-Hong Ignatius Ou; Thanyanan Reungwetwattana; Pasi A Jänne; Tony S Mok; Heather A Wakelee; Robert Pirker; Julien Mazières; Julie R Brahmer; Yang Zhou; Roy S Herbst; Vassiliki A Papadimitrakopoulou; Mary W Redman; Murry W Wynes; David R Gandara; Ronan J Kelly; Fred R Hirsch; Harvey I Pass
Journal:  J Thorac Oncol       Date:  2016-03-22       Impact factor: 15.609

5.  Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors.

Authors:  Jamie E Chaft; Matthew D Hellmann; Moises J Velez; William D Travis; Valerie W Rusch
Journal:  Ann Thorac Surg       Date:  2017-09       Impact factor: 4.330

6.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

7.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

8.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials.

Authors:  Wei-An Song; Nai-Kang Zhou; Wei Wang; Xiang-Yang Chu; Chao-Yang Liang; Xiao-Dong Tian; Jun-Tang Guo; Xi Liu; Yang Liu; Wei-Min Dai
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.